![](/img/cover-not-exists.png)
Cost-Effectiveness Analysis of Nilotinib Versus High-Dose Imatinib for the Second-Line Treatment of Chronic Myeloid Leukemia In China : Based on Nation-Wide Data
Guan, L, Huang, C, Liu, YVolume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.04.1712
Date:
May, 2018
File:
PDF, 82 KB
english, 2018